NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
19.22
+0.85 (4.63%)
At close: May 12, 2025, 4:00 PM
19.22
0.00 (0.00%)
After-hours: May 12, 2025, 4:39 PM EDT
NAMS Revenue
NewAmsterdam Pharma Company had revenue of $2.98M in the quarter ending March 31, 2025, with 112.56% growth. This brings the company's revenue in the last twelve months to $47.14M, up 586.97% year-over-year. In the year 2024, NewAmsterdam Pharma Company had annual revenue of $45.56M with 223.37% growth.
Revenue (ttm)
$47.14M
Revenue Growth
+586.97%
P/S Ratio
41.31
Revenue / Employee
$693,235
Employees
68
Market Cap
2.16B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 45.56M | 31.47M | 223.37% |
Dec 31, 2023 | 14.09M | -88.60M | -86.28% |
Dec 31, 2022 | 102.69M | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
NAMS News
- 4 days ago - NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results - GlobeNewsWire
- 5 days ago - NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025 - GlobeNewsWire
- 10 days ago - NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 12 days ago - NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress - GlobeNewsWire
- 6 weeks ago - NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 2 months ago - NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib - Seeking Alpha
- 2 months ago - NewAmsterdam Pharma: A Mispriced Bet On A Cholesterol Revolution - Seeking Alpha
- 2 months ago - NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire